<DOC>
	<DOC>NCT01662674</DOC>
	<brief_summary>This study is to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.</brief_summary>
	<brief_title>BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Age between 20 to 45, healthy male subjects(at screening) Body weight between 55kg 90kg, BMI between 18.0 27.0 FPG 70125mg/dL glucose level(at screening) Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress. Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.) Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included) Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics) Subject who already participated in other trials in 3months Subject who had whole blood donation in 2months, or component blood donation in 1months or transfusion in 1months currently. Smokers.(but, if the subject did'nt smoke in 3months, can participate the trial)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>